Arcus Biosciences (RCUS) Tops Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. SPOT
6. BYD
7. BE
8. SPY
9. WCN
10. NDAQ

Go back to Arcus Biosciences (RCUS) Tops Q3 EPS by 2c

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

November 6, 2024 4:22 PM EST

Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the... More